5H-Pyrrolo[3,4-D]pyrimidine | 671-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 5H-Pyrrolo[3,4-D]pyrimidine
• CAS: 671-23-8
• 化学式: C₆H₅N₃
• 分子量: 119.12
• InChiKey: SAHJOSKPGKTZTC-UHFFFAOYSA-N

物化性质

• 沸点：
  280.6±29.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Ibrahim Prabha N.

  公开号：US20140128373A1

  公开（公告）日：2014-05-08

  Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

  描述了对蛋白激酶活性有效的化合物，以及制备和使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病况的方法。
• 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)
  申请人：Foote Michael Kevin

  公开号：US20080045517A1

  公开（公告）日：2008-02-21

  The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  该发明涉及一组新型噻吩-吡咯化合物，其化学式为(I)：其中：R1、R2、R3、R4和R5如规范中所定义，这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及该化合物的制药配方、使用该化合物的治疗方法以及制备该化合物的过程。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Plexxikon Inc.

  公开号：US20160068528A1

  公开（公告）日：2016-03-10

  Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

  公式（I）的杂环化合物，其制备方法，含有此类化合物的制药组合物以及它们的治疗用途。
• Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
  申请人：——

  公开号：US20040171030A1

  公开（公告）日：2004-09-02

  Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers has a modified base for binding to a cytosine, uracil, or thymine base in the opposite strand. Oligonucleotide/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein the oligomer has a modified base for binding to a cytosine, uracil, or thymine base in the opposite strand.
• Hydroxypiperidine derivatives and uses thereof
  申请人：Ohler Norman E.

  公开号：US20110178066A1

  公开（公告）日：2011-07-21

  Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.